Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial.

Lengsfeld S, Burkard T, Meienberg A, Jeanloz N, Vukajlovic T, Bologna K, Steinmetz M, Bathelt C, Sailer CO, Vogt DR, Hemkens LG, Speich B and 7 more

Show all authors

Urwyler SA, Kühne J, Baur F, Lutz LN, Erlanger TE, Christ-Crain M, Winzeler B

EClinicalMedicine21 Feb 2023Cited by 69 (Europe PMC)

PMID36874396PMCIDPMC9981899DOI10.1016/j.eclinm.2023.101865PepBankPUB-36874396

Read at source PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adult smokers, dulaglutide did not improve abstinence compared with placebo.
In plain wordsIn adult smokers, dulaglutide did not improve quitting rates compared with placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeSmoking abstinence
Study
n = 255
Comparator
Placebo
Analysis
Primary
Outcome group
Addiction, withdrawal and alcohol intake · Whole body
Studied dose
1.5 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Abstinence rate at week 12
63%
dulaglutide (80/127)
Abstinence rate at week 12
65%
placebo (83/128)
Difference in abstinence proportions
−1.9%
dulaglutide vs placebo
95% confidence interval of difference in proportions
−10.7 to 14.4%
dulaglutide vs placebo
p value
0.859
abstinence, between groups
Source sentences
Summary
After 12 weeks, 63% (80/127) participants on dulaglutide and 65% (83/128) on placebo treatment were abstinent (difference in proportions -1.9% [95% Confidence interval (CI) -10.7, 14.4], p-value (p) = 0.859).
1 context sentence(design, population, supporting numbers)
Summary · context
We included adult smokers with at least moderate cigarette dependence who wanted to quit. Participants were randomly assigned to a 12-week treatment with dulaglutide 1.5 mg once weekly or placebo subcutaneously in addition to standard of care including behavioural counselling and oral varenicline ph…
Report a problemFND-3687439601
02HumanRandomized controlled trialEfficacy outcome
In adult smokers, dulaglutide reduced post-cessation weight compared with placebo.
In plain wordsIn adult smokers, dulaglutide reduced weight compared with placebo during smoking cessation.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePost-cessation weight change
Study
n = 255
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Weight change
−1 kg
dulaglutide, SD 2.7
Weight change
1.9 kg
placebo, SD 2.4
Baseline-adjusted difference in weight change
−2.9 kg
dulaglutide vs placebo
95% confidence interval of adjusted weight difference
−3.59 to −2.3 kg
dulaglutide vs placebo
p value
< 0.001
adjusted weight difference
Source sentences
Summary
The baseline-adjusted difference in weight change between groups was -2.9 kg (95% CI -3.59, -2.3, p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Dulaglutide decreased post-cessation weight (-1 kg [standard deviation (SD) 2.7]), while weight increased on placebo (+1.9 kg [SD 2.4]).
Summary · context
We included adult smokers with at least moderate cigarette dependence who wanted to quit. Participants were randomly assigned to a 12-week treatment with dulaglutide 1.5 mg once weekly or placebo subcutaneously in addition to standard of care including behavioural counselling and oral varenicline ph…
Report a problemFND-3687439602
03HumanRandomized controlled trialEfficacy outcome
In adult smokers, dulaglutide reduced HbA1c compared with placebo.
In plain wordsIn adult smokers, dulaglutide reduced HbA1c more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c
Study
n = 255
Comparator
Placebo
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Baseline-adjusted median difference in HbA1c
−0.25%
dulaglutide vs placebo
Interquartile range of HbA1c difference
−0.36 to −0.14%
dulaglutide vs placebo
p value
< 0.001
HbA1c difference
Source sentences
Summary
Haemoglobin A1c (HbA1c) level declined on dulaglutide treatment (baseline-adjusted median difference in HbA1c between groups -0.25% [interquartile range (IQR) -0.36, -0.14], p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We included adult smokers with at least moderate cigarette dependence who wanted to quit. Participants were randomly assigned to a 12-week treatment with dulaglutide 1.5 mg once weekly or placebo subcutaneously in addition to standard of care including behavioural counselling and oral varenicline ph…
Report a problemFND-3687439603
04HumanRandomized controlled trialEfficacy outcome
In adult smokers also receiving varenicline, craving for smoking declined during treatment in both groups with no difference between dulaglutide and placebo.
In plain wordsIn adult smokers, craving fell in both groups, with no difference between dulaglutide and placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeSmoking craving
Study
n = 255
Comparator
Placebo
Analysis
Secondary
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
1.5 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Craving for smoking declined during treatment without any difference between the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
We included adult smokers with at least moderate cigarette dependence who wanted to quit. Participants were randomly assigned to a 12-week treatment with dulaglutide 1.5 mg once weekly or placebo subcutaneously in addition to standard of care including behavioural counselling and oral varenicline ph…
Report a problemFND-3687439604
05HumanRandomized controlled trialSafety outcome
In adult smokers, reported gastrointestinal symptom rates were 90% with dulaglutide and 81% with placebo, but the placebo count and percentage conflict.
In plain wordsIn adult smokers, gastrointestinal symptoms were numerically more frequent with dulaglutide than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseGastrointestinal symptoms
Study
n = 255
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.5 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Treatment-emergent gastrointestinal symptoms
90%
dulaglutide (114/127)
Treatment-emergent gastrointestinal symptoms
81%
placebo (81/128, as written)
Source sentences
Summary
Treatment-emergent gastrointestinal symptoms were very common in both groups: 90% (114/127) of participants on dulaglutide and 81% (81/128) on placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
We included adult smokers with at least moderate cigarette dependence who wanted to quit. Participants were randomly assigned to a 12-week treatment with dulaglutide 1.5 mg once weekly or placebo subcutaneously in addition to standard of care including behavioural counselling and oral varenicline ph…
Report a problemFND-3687439605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT03204396

Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues

University Hospital, Basel, Switzerlandn = 25626 Jun 2017 to 30 Aug 2022

Glucagon-like Peptide-1 · Smoking Cessation · Weight Change, Body · Craving

Trial page ClinicalTrials.govUpdated 13 Sept 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.